L Kobylinska1,2, A M Panaitescu3, G Gabreanu4, C G Anghel1,5, I Mihailescu1, F Rad1,5, C Nedelcu1, I Mocanu1, C Constantin6, S V Badescu2, I Dobrescu1,5, M Neagu6, O I Geicu7, L Zagrean2, A M Zagrean2. 1. "Prof. Dr. Al. Obregia" Clinical Psychiatry Hospital - Child and Adolescent Psychiatry, Bucharest, Romania. 2. "Carol Davila" University of Medicine and Pharmacy - Division of Physiology and Fundamental Neuroscience, Bucharest, Romania. 3. Filantropia Hospital, Bucharest, Romania. 4. "Victor Babes" National Institute of Research-Development in the Pathology Domain and Biomedical Sciences - Dept. of Immunohistochemistry, Bucharest, Romania. 5. "Carol Davila" University of Medicine and Pharmacy - Dept. of Child and Adolescent Psychiatry, Bucharest, Romania. 6. "Victor Babes" National Institute of Research-Development in the Pathology Domain and Biomedical Sciences - Dept. of Immunology, Bucharest, Romania. 7. University of Bucharest, Faculty of Biology, Dept. of Biochemistry and Molecular Biology, Bucharest, Romania.
Abstract
CONTEXT: Oxytocin has been investigated as a potential medication for psychiatric disorders. OBJECTIVE AND DESIGN: This study prospectively investigates correlations between oxytocin and other neuropeptides plasma levels in patients with autism spectrum disorders (ASD) according to severity and treatment, as compared to controls. SUBJECTS AND METHODS: Thirty-one children (6 neurotypical as control) participated in this study. The patients were classified into mildly and severely-affected, according to Autism Diagnostic Observation Schedule (ADOS) scores. Oxytocin, orexin A and B, α-MSH, β-endorphins, neurotensin and substance P were investigated using a quantitative multiplex assay or a competitive-ELISA method. RESULTS: Plasma oxytocin levels differed between the groups (F (2, 24) =6.48, p=0.006, η2=0.35, observed power=86%): patients with the mild ASD had higher values of plasma oxytocin than those with the severe form (average difference=74.56±20.74pg/mL, p=0.004). CONCLUSIONS: These results show a negative correlation between plasma levels of oxytocin and the severity of ASD and support the involvement of oxytocinergic mechanisms in ASD.
CONTEXT: Oxytocin has been investigated as a potential medication for psychiatric disorders. OBJECTIVE AND DESIGN: This study prospectively investigates correlations between oxytocin and other neuropeptides plasma levels in patients with autism spectrum disorders (ASD) according to severity and treatment, as compared to controls. SUBJECTS AND METHODS: Thirty-one children (6 neurotypical as control) participated in this study. The patients were classified into mildly and severely-affected, according to Autism Diagnostic Observation Schedule (ADOS) scores. Oxytocin, orexin A and B, α-MSH, β-endorphins, neurotensin and substance P were investigated using a quantitative multiplex assay or a competitive-ELISA method. RESULTS: Plasma oxytocin levels differed between the groups (F (2, 24) =6.48, p=0.006, η2=0.35, observed power=86%): patients with the mild ASD had higher values of plasma oxytocin than those with the severe form (average difference=74.56±20.74pg/mL, p=0.004). CONCLUSIONS: These results show a negative correlation between plasma levels of oxytocin and the severity of ASD and support the involvement of oxytocinergic mechanisms in ASD.
Authors: Elena V Kozlova; Matthew C Valdez; Maximillian E Denys; Anthony E Bishay; Julia M Krum; Kayhon M Rabbani; Valeria Carrillo; Gwendolyn M Gonzalez; Gregory Lampel; Jasmin D Tran; Brigitte M Vazquez; Laura M Anchondo; Syed A Uddin; Nicole M Huffman; Eduardo Monarrez; Duraan S Olomi; Bhuvaneswari D Chinthirla; Richard E Hartman; Prasada Rao S Kodavanti; Gladys Chompre; Allison L Phillips; Heather M Stapleton; Bernhard Henkelmann; Karl-Werner Schramm; Margarita C Curras-Collazo Journal: Arch Toxicol Date: 2021-10-23 Impact factor: 5.153
Authors: Rosa Marotta; Maria C Risoleo; Giovanni Messina; Lucia Parisi; Marco Carotenuto; Luigi Vetri; Michele Roccella Journal: Brain Sci Date: 2020-03-13